Tarsus Q2 net product sales $102.7M, up 152% YoY; net loss narrows to $20.3M

Tarsus Pharmaceuticals, Inc.

2025-Q2 EPS reported -$1.11 revenue$180,995,000

Record Q2 net product sales $102.7M (+152% YoY); 91,000 bottles distributed.
Net loss $20.3M ($0.48 loss per share) vs $33.3M ($0.88) in Q2 2024.
Gross-to-net discount ~45%; DTC campaign drove 400% web engagement and 30% more prescribers.
Cash $381.1M; pipeline: Phase 2 TP-04 (ocular rosacea) H2 2025, TP-05 (Lyme) in 2026.
Global expansion: Japan regulatory meetings H2 2025; EU approval expected 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.